Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

Translocations involving c-myc and an Ig locus have been reported rarely in human multiple myeloma (MM). Using specific fluorescence in situ hybridization probes, we show complex karyotypic abnormalities of the c-myc or L-myc locus in 19 of 20 MM cell lines and approximately 50% of advanced primary MM tumors. These abnormalities include unusual and complex translocations and insertions that often juxtapose myc with an IgH or IgL locus. For two advanced primary MM tumors, some tumor cells contain a karyotypic abnormality of the c-myc locus, whereas other tumor cells do not, indicating that this karyotypic abnormality of c-myc occurs as a late event. All informative MM cell lines show monoallelic expression of c-myc. For Burkitt's lymphoma and mouse plasmacytoma tumors, balanced translocation that juxtaposes c-myc with one of the Ig loci is an early, invariant event that is mediated by B cell-specific DNA modification mechanisms. By contrast, for MM, dysregulation of c-myc apparently is caused principally by complex genomic rearrangements that occur during late stages of MM progression and do not involve B cell-specific DNA modification mechanisms.

[1]  R. Bataille,et al.  High incidence of cryptic translocations involving the Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization , 1999, Genes, chromosomes & cancer.

[2]  P. L. Bergsagel,et al.  Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. , 1999, Molecular cell.

[3]  B. Barlogie,et al.  Identification of New Nonrandom Translocations in Multiple Myeloma With Multicolor Spectral Karyotyping , 1998 .

[4]  J. Westwick,et al.  Chemokines and T lymphocytes: more than an attraction. , 1998, Immunity.

[5]  E. Schröck,et al.  Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. , 1998, Blood.

[6]  U. Klein,et al.  Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  F. Mills,et al.  Enhancer Complexes Located Downstream of Both Human Immunoglobulin Cα Genes , 1997, The Journal of experimental medicine.

[8]  M. Taniwaki,et al.  The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. , 1997, Blood.

[9]  E. Schröck,et al.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.

[10]  J. Cigudosa,et al.  Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations , 1997, Genes, chromosomes & cancer.

[11]  P. L. Bergsagel,et al.  IgH translocations in multiple myeloma: a nearly universal event that rarely involves c-myc. , 1997, Current topics in microbiology and immunology.

[12]  P. L. Bergsagel,et al.  Dysregulation of c-myc in multiple myeloma. , 1997, Current topics in microbiology and immunology.

[13]  D. Zimonjic,et al.  Molecular cytogenetic characterization of cancer cell alterations. , 1997, Cancer genetics and cytogenetics.

[14]  P. L. Bergsagel,et al.  Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  W. Kuehl,et al.  Selective expression of one c-myc allele in two human myeloma cell lines. , 1996, Cancer research.

[16]  B. Barlogie,et al.  Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.

[17]  J. Mary,et al.  Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. , 1995, Blood.

[18]  M. Potter,et al.  Differences in the molecular structure of c-myc-activating recombinations in murine plasmacytomas and precursor cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Jourdan,et al.  Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. , 1994, Blood.

[20]  N. Carter,et al.  A map of the human immunoglobulin VH locus completed by analysis of the telomeric region of chromosome 14q , 1994, Nature Genetics.

[21]  Ilan R. Kirsch,et al.  The Causes and Consequences of Chromosomal Aberrations , 1992 .

[22]  M. Pettersson,et al.  Expression of myc‐family genes in established human multiple myeloma cell lines: L‐myc but not c‐myc gene expression in the U‐266 myeloma cell line , 1992, International journal of cancer.

[23]  S. Korsmeyer,et al.  Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. , 1992, Annual review of immunology.

[24]  H. Asaoku,et al.  Increased expression of the c‐myc gene may be related to the aggressive transformation of human myeloma cells , 1991, British journal of haematology.

[25]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[26]  R. Benner,et al.  Amplification of the c-myc and the pvt-like region in human multiple myeloma. , 1990, Oncogene.

[27]  M. Taniwaki,et al.  Amylase-producing plasmacytoma cell lines, AD3 and FR4, with der(14)t(8;14) and dic(8)t(1;8) established from ascites. , 1990, Leukemia.

[28]  O. Olopade,et al.  Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11) , 1990, Genes, chromosomes & cancer.

[29]  P. Sherrington,et al.  A new human plasma cell line, Karpas 620, with translocations involving chromosomes 1, 11 and 14 , 1990, British journal of haematology.

[30]  J. S. Lee,et al.  Long-distance activation of the Myc protooncogene by provirus insertion in Mlvi-1 or Mlvi-4 in rat T-cell lymphomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Boccadoro,et al.  The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. , 1989, Blood.

[32]  T. Grogan,et al.  Myelomonocytic myeloma cell line (LB 84-1). , 1989, Blood.

[33]  J. Gerdes,et al.  Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67. , 1988 .

[34]  W. O'Fallon,et al.  Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. , 1988, Blood.

[35]  A. Gazdar,et al.  Complex translocation disrupts c-myc regulation in a human plasma cell myeloma , 1988, Molecular and cellular biology.

[36]  J. Battey,et al.  Structure and expression of the human L-myc gene reveal a complex pattern of alternative mRNA processing , 1988, Molecular and cellular biology.

[37]  J. Battey,et al.  Human small-cell lung cancers show amplification and expression of the N-myc gene. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Korsmeyer,et al.  Translocations that highlight chromosomal regions of differentiated activity. , 1985, Cancer genetics and cytogenetics.

[39]  S. Tarui,et al.  Two distinct human myeloma cell lines originating from one patient with myeloma , 1985, International journal of cancer.

[40]  R. Kyle,et al.  The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. , 1985, Blood.